Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

This brand new ‘vaccine’ can produce immune response against COVID-19; Read details

PTI
Updated: July 15th, 2020, 11:09 IST
in Coronavirus, Feature
0
Vaccine

Photo courtesy: mbtmag.com

Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Washington: An experimental COVID-19 vaccine developed by the American biotech company Moderna prompted neutralising antibody activity in healthy adults, though it led to minor side effects in many patients, according to a new study from the preliminary stages of an ongoing trial.

This initial findings, published in The New England Journal of Medicine, is from the first 45 participants of ages 18 to 55 years enrolled at the study sites in Seattle and at Emory University in the US.

Also Read

Celebrating nature’s coastal guardians

10 hours ago
Viral video

Viral video: She wanted likes, but got bruise instead; here’s how

1 day ago

According to the study, the investigational vaccine — mRNA-1273 — induced immune responses against the novel coronavirus SARS-CoV-2 in all participants, “and no trial-limiting safety concerns were identified.”

The researchers, led by Lisa A. Jackson from Washington Health Research Institute in the US, said mRNA-1273is designed to induce neutralising antibodies directed at a portion of the novel coronavirus “spike” protein, which the virus uses to bind to and enter human cells.

They said it is being co-developed by researchers at the the National Institute of Allergy and Infectious Diseases (NIAID), and at Moderna, Inc. of Cambridge, Massachusetts in the US.

In the study, three groups of 15 participants received two intramuscular injections, 28 days apart, of either 25, 100, or 250 microgrammes (mcg) of the investigational vaccine.

The scientists noted that all the participants received one injection, and 42 received both scheduled injections.

They said in April the trial was expanded to enrol adults older than age 55 years, with 120 individual participating now.

However, the researchers said the newly published results cover only the 18 to 55-year age group.

From the current study, the said no serious adverse events were reported from the use of the experimental vaccine.

However, the scientists said more than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site.

They explained that systemic adverse events were more common following the second vaccination, and in those who received the highest vaccine dose.

Commenting on the findings, Andrew Freedman from the University of Cardiff in the UK, who is an infectious disease expert unrelated to the research, said most of the reported side effects are common after vaccination.

“The side effects experienced by more than half the participants are quite common after other vaccinations, although the ‘more severe adverse events’ experienced by three of the subjects given the highest dose may mean that dose is too high to take forward,” Freedman said in a statement to the press.

Using this data on side effects and immune responses at various vaccine dosages, the study scientists have formulated doses planned for use in the Phase 2 and 3 clinical trials of mRNA-1273.

“Phase 2 studies of this vaccine are already underway, but it will require larger, phase 3 studies to be completed to determine whether it is effective in preventing COVID-19,” Freedman noted.

The interim analysis, according to the study authors, includes results of tests measuring levels of vaccine-induced neutralising activity through day 43 after the second injection.

They said two doses of the experimental vaccine prompted high levels of neutralising antibody activity that were above the average values seen in convalescent sera obtained from persons with confirmed COVID-19 disease.

With a phase 2 clinical trial of mRNA-1273, beginning enrolment in late May, the researchers said plans are currently underway to launch a Phase 3 efficacy trial this month.

PTI

Tags: Coronaviruscovid19Modernavaccine
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

slide 2 to 4 of 30
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Aman Kumar Barisal

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Matrumangal Jena

December 12, 2019
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
#MyPaperBagChallenge

Dibya Ranjan Das

December 12, 2019
#MyPaperBagChallenge

Sibarama Khotei

December 12, 2019
#MyPaperBagChallenge

Tapaswini Mallick

December 12, 2019
#MyPaperBagChallenge

Aishwarya Ranjan Mohanty

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Sarfraz Ahmad

December 12, 2019
#MyPaperBagChallenge

Swarit Praharaj

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Pratyasharani Ghibela

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019

Archives

Select Month

    Editorial

    Honeytrap Alarm

    July 26, 2025

    If your password is still “1234” and you think a luxury hotel room is a safe space, you’re probably not...

    Read more

    Exit Mystery

    Jagdeep Dhankhar
    July 23, 2025

    A major controversy has erupted after the sudden resignation of Vice President Jagdeep Dhankhar, tendered hours after he had attended...

    Read more

    Voting At 16

    Ballot Box
    July 22, 2025

    It has long been held that when one is young, one tends to subscribe to pro-poor and people-oriented progressive politics,...

    Read more

    Water Bomb

    OPiate
    July 21, 2025

    On 19 July, China began constructing a $167.8 billion dam on the Brahmaputra River in Tibet, close to the Indian...

    Read more
    • Home
    • State
    • Metro
    • National
    • International
    • Business
    • Editorial
    • Opinion
    • Sports
    • About Us
    • Advertise
    • Contact Us
    • Jobs
    Developed By Ratna Technology

    © 2024 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2024 All rights Reserved by OrissaPOST

      • News in Odia
      • Orissa POST Epaper
      • Video
      • Home
      • Trending
      • Metro
      • State
      • Odisha Special
      • National
      • International
      • Sports
      • Business
      • Editorial
      • Entertainment
      • Horoscope
      • Careers
      • Feature
      • Today’s Pic
      • Opinion
      • Sci-Tech
      • About Us
      • Contact Us
      • Jobs

      © 2024 All rights Reserved by OrissaPOST